Introduction: The present study investigated whether it is possible to predict the medium term response to venlafaxine using biological markers and psychophysiological methods.
Material: Fourteen (14) patients aged 21-60 years suffering from Major Depression according to DSM-IV were included in the study.
Methods: The SCAN v 2.0 and the IPDE were used to assist clinical diagnosis. Patients were investigated with electrooculogram (EOG), Pattern-Reversal Visual Evoked Potentials (PR-VEPs), Dexamethasone Suppression Test (DST), D-fenfluramine Challenge Test, and brain Single Photon Emission Tomography (SPECT). Venlafaxine 150-225 mg per os daily was administered. The follow-up period was 2 years.
Statistical Analysis: Chi-square test and ANOVA were used for the analysis of data.
Results: There was a lower left globus pallidus regional cerebral blood flow in patients with better response. On the contrary, chronic patients were closer to normality.
Discussion: The results of the current study provide preliminary evidence concerning our ability to predict response to venlafaxine and to understand its way of action.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jad.2006.09.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An Exploration of the Interplay Between Caffeine and Antidepressants Through the Lens of Pharmacokinetics and Pharmacodynamics.
Eur J Drug Metab Pharmacokinet
January 2025
Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Caffeine consumption is regarded as a widespread phenomenon, and its usage has continued to increase. In addition, the growing usage of antidepressants worldwide and increase in mental health disorders were shown in recent statistical analyses conducted by the World Health Organisation. The coadministration of caffeine and antidepressants remains a concern due to potential interactions that can alter a patient's response to therapy.
View Article and Find Full Text PDFThe Significance of Psychological Support in Managing Depression in Parkinson's Disease: Combining Venlafaxine with Pramipexole and Psychological Care.
Actas Esp Psiquiatr
January 2025
Neurology Department, Geriatric Hospital of Hainan, 571100 Haikou, Hainan, China.
Background: Depression is a common comorbidity in patients with Parkinson's disease (PD) and can significantly impact their overall well-being. The combination of venlafaxine and pramipexole is a standard treatment approach for depression in PD. However, the effects of incorporating psychological care into the treatment regimen remain unclear.
View Article and Find Full Text PDFFirst Episode Psychosis in a Teen with Narcolepsy and Cataplexy.
Psychopharmacol Bull
January 2025
Abhishek Reddy, MD, Assistant Professor, Child and Adolescent Psychiatry, Sleep Medicine, Department of Psychiatry, Virginia Tech Carilion School of Medicine, Roanoke, VA, United States.
Article Synopsis
- Narcolepsy with cataplexy (NT1) is a rare sleep disorder that can be linked to early-onset psychosis, particularly in kids and teens.
- After excluding other medical issues, an adolescent girl with NT1 was initially diagnosed with a brief psychotic episode and treated with Risperidone.
- Her symptoms improved significantly after switching to Chlorpromazine, marking one of the first successful uses of this drug for managing first-episode psychosis in a patient with NT1.
Ansofaxine suppressed NSCLC progression by increasing sensitization to combination immunotherapy.
Int Immunopharmacol
January 2025
School of Medicine, Guizhou University, Guiyang 550025, China; NHC Key Laboratory of Pulmonary Immunological Diseases, Guizhou Provincial People's Hospital, Guiyang 550002, China. Electronic address:
Introduction: Depression negatively impacts the prognosis of various cancers, including lung cancer, by influencing antitumor immune responses and impairing immune cell function. Antidepressants may modulate the tumor immune microenvironment, enhancing immunotherapy efficacy. However, the specific mechanisms remain unclear.
View Article and Find Full Text PDFGenetic Variants and Major Depressive Disorder: A Systematic Review.
Pharmaceuticals (Basel)
October 2024
Clinical Analysis Laboratory, Molecular Pathology Sector, Pharmacy Department, Faculty of Ceilândia, University of Brasília (UnB), Brasília-Federal District (DF), Brasília 72220-900, Brazil.
Article Synopsis
- Major depressive disorder (MDD) impacts over 300 million people worldwide and has various causes, with the CYP2C19 enzyme affecting how some antidepressants are metabolized.
- A systematic review followed specific protocols and found only nine relevant studies from 240 articles that met inclusion criteria regarding gene variant frequencies and their effects on MDD.
- While some genetic variants showed associations with MDD symptoms and treatment responses, results were inconsistent, indicating a need for more research to better understand these genetic influences on depression and improve treatment options.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!